Cargando…

Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study

The prognosis of leptomeningeal metastasis (LM) from solid tumors is extremely poor, especially for patients with adverse prognostic factors. In this phase II clinical trial, we evaluated the efficacy and safety of intrathecal chemotherapy (IC) combined with concomitant involved‐field radiotherapy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Zhenyu, Yang, Guozi, He, Hua, Zhao, Gang, Yuan, Tingting, Li, Yu, Shi, Weiyan, Gao, Pengxiang, Dong, Lihua, Li, Yunqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096248/
https://www.ncbi.nlm.nih.gov/pubmed/27243238
http://dx.doi.org/10.1002/ijc.30214
_version_ 1782465434165968896
author Pan, Zhenyu
Yang, Guozi
He, Hua
Zhao, Gang
Yuan, Tingting
Li, Yu
Shi, Weiyan
Gao, Pengxiang
Dong, Lihua
Li, Yunqian
author_facet Pan, Zhenyu
Yang, Guozi
He, Hua
Zhao, Gang
Yuan, Tingting
Li, Yu
Shi, Weiyan
Gao, Pengxiang
Dong, Lihua
Li, Yunqian
author_sort Pan, Zhenyu
collection PubMed
description The prognosis of leptomeningeal metastasis (LM) from solid tumors is extremely poor, especially for patients with adverse prognostic factors. In this phase II clinical trial, we evaluated the efficacy and safety of intrathecal chemotherapy (IC) combined with concomitant involved‐field radiotherapy (IF‐RT) for treating LM from solid tumors with adverse prognostic factors. Fifty‐nine patients with LM from various solid tumors were enrolled between May 2010 and December 2014. Concurrent therapy consisted of concomitant IC (methotrexate 12.5–15 mg and dexamethasone 5 mg, weekly) and IF‐RT (whole brain and/or spinal canal RT, 40 Gy/20f). For patients with low Karnofsky performance status (KPS) score and radiotherapy intolerance, induction IC (1–3 times) was given before concurrent therapy. Thirty‐eight patients (64.4%) received subsequent treatments. All patients were followed up at least 6 months after LM diagnosis or until death. Primary endpoint evaluated was clinical response rate. Secondary endpoints were overall survival (OS) and safety. The pathological types included lung cancer (n = 42), breast cancer (n = 11) and others (n = 6). Median KPS score was 40 (range 20–70). Fifty‐one patients (86.4%) completed concurrent therapy. The overall response rate was 86.4% (51/59). OS ranged from 0.4 to 36.7 months (median 6.5 months), and 1‐year‐survival rate was 21.3%. Treatment‐related adverse events mainly included acute meningitis, chronic‐delayed encephalopathy, radiculitis, myelosuppression and mucositis. Twelve patients (20.3%) had grade III–V toxic reactions. We concluded that IC combined with concomitant IF‐RT, with significant efficacy and acceptable toxicity, may be an optimal therapeutic option for treatment of LM from solid tumors with adverse prognostic factors. LM, in which cancer cells spread to membranes enveloping the brain and spinal cord, is a devastating complication of solid cancers. Existing LM therapies center on IC. In this prospective clinical study, the authors combined intrathecal methotrexate with involved‐field radiotherapy in a concomitant regimen, showing that the approach can potentially improve quality of life for patients with adverse prognostic factors. Concurrent radiotherapy‐bolstered IC by contributing to prolonged remission of neurological symptoms and increasing OS. The findings suggest that the concomitant regimen could be an optimal treatment option for LM.
format Online
Article
Text
id pubmed-5096248
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50962482016-11-09 Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study Pan, Zhenyu Yang, Guozi He, Hua Zhao, Gang Yuan, Tingting Li, Yu Shi, Weiyan Gao, Pengxiang Dong, Lihua Li, Yunqian Int J Cancer Cancer Therapy and Prevention The prognosis of leptomeningeal metastasis (LM) from solid tumors is extremely poor, especially for patients with adverse prognostic factors. In this phase II clinical trial, we evaluated the efficacy and safety of intrathecal chemotherapy (IC) combined with concomitant involved‐field radiotherapy (IF‐RT) for treating LM from solid tumors with adverse prognostic factors. Fifty‐nine patients with LM from various solid tumors were enrolled between May 2010 and December 2014. Concurrent therapy consisted of concomitant IC (methotrexate 12.5–15 mg and dexamethasone 5 mg, weekly) and IF‐RT (whole brain and/or spinal canal RT, 40 Gy/20f). For patients with low Karnofsky performance status (KPS) score and radiotherapy intolerance, induction IC (1–3 times) was given before concurrent therapy. Thirty‐eight patients (64.4%) received subsequent treatments. All patients were followed up at least 6 months after LM diagnosis or until death. Primary endpoint evaluated was clinical response rate. Secondary endpoints were overall survival (OS) and safety. The pathological types included lung cancer (n = 42), breast cancer (n = 11) and others (n = 6). Median KPS score was 40 (range 20–70). Fifty‐one patients (86.4%) completed concurrent therapy. The overall response rate was 86.4% (51/59). OS ranged from 0.4 to 36.7 months (median 6.5 months), and 1‐year‐survival rate was 21.3%. Treatment‐related adverse events mainly included acute meningitis, chronic‐delayed encephalopathy, radiculitis, myelosuppression and mucositis. Twelve patients (20.3%) had grade III–V toxic reactions. We concluded that IC combined with concomitant IF‐RT, with significant efficacy and acceptable toxicity, may be an optimal therapeutic option for treatment of LM from solid tumors with adverse prognostic factors. LM, in which cancer cells spread to membranes enveloping the brain and spinal cord, is a devastating complication of solid cancers. Existing LM therapies center on IC. In this prospective clinical study, the authors combined intrathecal methotrexate with involved‐field radiotherapy in a concomitant regimen, showing that the approach can potentially improve quality of life for patients with adverse prognostic factors. Concurrent radiotherapy‐bolstered IC by contributing to prolonged remission of neurological symptoms and increasing OS. The findings suggest that the concomitant regimen could be an optimal treatment option for LM. John Wiley and Sons Inc. 2016-06-30 2016-10-15 /pmc/articles/PMC5096248/ /pubmed/27243238 http://dx.doi.org/10.1002/ijc.30214 Text en © 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Cancer Therapy and Prevention
Pan, Zhenyu
Yang, Guozi
He, Hua
Zhao, Gang
Yuan, Tingting
Li, Yu
Shi, Weiyan
Gao, Pengxiang
Dong, Lihua
Li, Yunqian
Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
title Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
title_full Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
title_fullStr Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
title_full_unstemmed Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
title_short Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
title_sort concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single‐arm study
topic Cancer Therapy and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096248/
https://www.ncbi.nlm.nih.gov/pubmed/27243238
http://dx.doi.org/10.1002/ijc.30214
work_keys_str_mv AT panzhenyu concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT yangguozi concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT hehua concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT zhaogang concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT yuantingting concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT liyu concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT shiweiyan concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT gaopengxiang concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT donglihua concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy
AT liyunqian concurrentradiotherapyandintrathecalmethotrexatefortreatingleptomeningealmetastasisfromsolidtumorswithadverseprognosticfactorsaprospectiveandsinglearmstudy